TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. has announced a capital increase agreement involving its non-wholly owned subsidiary, JunTop Biosciences, and Shanghai Tanying Investment Partnership. This transaction, which is classified as a related party transaction under PRC laws, does not constitute a connected transaction under Hong Kong’s Listing Rules. The agreement signifies a strategic move to bolster financial resources, potentially enhancing the company’s market position and operational capabilities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, particularly in the field of immuno-oncology.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.